Type B insulin resistance syndrome induced by increased activity of systemic lupus erythematosus in a hemodialysis patient

Clinical Nephrology

Volumn 69, Issue 2, 2008, Pages 130-134

  Nagayama, Y ^a   Morita, H ^a   Komukai, D ^a   Watanabe, S ^a   Yoshimura, A ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Hemodialysis; Insulin receptor antibody; Lupus activity; Systemic lupus erythematosus; Type B insulin resistance syndrome

Indexed keywords

ANTINUCLEAR ANTIBODY; C PEPTIDE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; GALLIUM; GLUCOSE; INSULIN; INSULIN I 125; INSULIN RECEPTOR ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ACANTHOSIS NIGRICANS; ADRENAL INSUFFICIENCY; ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DUODENUM ULCER; FATALITY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMORRHAGIC SHOCK; HUMAN; HYPERGLYCEMIA; HYPOCOMPLEMENTEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LYMPHOCYTOPENIA; METABOLIC SYNDROME X; PNEUMOCYSTIS PNEUMONIA; SCINTIGRAPHY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 38949156153     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69130     Document Type: Article

References (21)

1. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of auto-antibodies to the insulin receptor (Type B insulin resistance). A 28-year perspective. Medicine, Baltimore. 2002; 81: 87-100.
2. Blecher M. Receptors, antibodies and disease. Clin Chem. 1984; 30: 1137-1156.
3. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH and the committee on prognosis studies in SLE. Derivation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum. 1992; 35: 630-640.
4. Bruce IN, Hallett DC, Gladman DD, Urowitz MB. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. J Rheumatol. 1999; 26: 1490-1494.
5. Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, Riggio RR, Robin AL. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis. 1990; 16: 189-195.
6. Coplon NS, Diskin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med. 1983; 308: 186-190.
7. De Pirro R, Roth RA, Rossetti L, Goldfine ID. Characterization of the serum from a patient with insulin resistance and hypoglycemia. Diabetes. 1984; 33: 301-304.
8. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie L, Li Y, Danoff D. Laboratoiy tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum. 1996; 39: 370-378.
9. Fries JF, Powers R, Kempson RL. Late-stage lupus nephropathy. J Rheumatol. 1974; 1: 166-175.
10. Goo YS, Park HC, Choi HY, Kim BS, Park YB, Lee SK, Kang SW, Kim SI, Kim YS, Park KI, Lee HY, Han DS, Choi KH. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis. Yonsei Med J. 2004; 45: 199-206.
11. Jarrett MP, Santhanam S, Del Greco F. The clinical course of end-stage renal disease in systemic lupus erythematosus. Arch Intern Med. 1983; 143: 1353-1356.
12. Kahn CR, Flier JS, Bar RS, Archer JA, Garden P, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976; 294: 739-745.
13. Krane NK, Burjak K, Archie M, O'Donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis. 1999; 33: 872-879.
14. Lee PT, Fang HC, Chen CL, Chiou YH, Chou KJ, Chung HM. Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus. 2003; 12: 827-832.
15. Nossent HC, Swaak TJG, Berden JHM for the Dutch Working Party on SLE. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Am J Med. 1990; 89: 169-174.
16. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence and clinical description of flare in systemic lupus erythematosus. Arthritis Rheum. 1991; 34: 937-944.
17. Ribeiro FM, Leite MAP, Velarde GC, Fabris CL, Santos RC, Lugon JR. Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort. Am J Nephrol. 2005; 25: 596-603.
18. Selinger S, Tsai J, Pulini M, Saperstein A, Taylor S. Autoimmune thrombocytopenia and primary biliary cirrhosis with hypoglycemia and insulin receptor autoantibodies. Ann Intern Med. 1987; 107: 686-688.
19. Taylor SI, Grunberger G, Marcus-Samuels B, Underhill LH, Dons RF, Ryan J, Roddam RF, Rupe CE, Gorden P. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med. 1982; 307: 1422-1426.
20. Taylor SI, Marcus-Samuels B. Anti-receptor antibodies mimic the effect of insulin to down-regulate insulin receptors in cultured human lymphoblastoid (IM-9) cells. J Clin Endocrinol Metab. 1984; 58: 182-186.
21. Weinstein PS, High KA, D'Ercole AJ, Jennette JC. Insulin resistance due to receptor antibodies: a complication of progressive systemic sclerosis. Arthritis Rheum. 1980; 23: 101-105.